Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameRaily Aesmed
Stock Code02135
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities於中國浙江省提供醫療美容服務,包括美容外科服務、微創美容服務及皮膚美容服務,並提供醫療美容管理諮詢服務。
Listing Date2020-12-28
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國杭州下城區中山北路290號民航大廈3–5樓
Business Address (Hong Kong)香港皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteruilizx.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 0.40 / shares
Offer Price RangeFinal offer price only, no range
Lot Size10,000 shares
Entry ThresholdHK$ 4,000
Par ValueTo be extracted
Offer Period2020-12-15 to 2020-12-18
Global Offering Shares342,500,000 shares
HK Public Offer Shares (Initial)34,250,000 shares (10.0%)
Public Offer Lots (Initial)3,425lots (Pool A1,712lots,Pool B1,713lots)
International Placing Shares (Initial)308,250,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO2,055,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share21.9%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 137,000,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 10,000 HK$ 4,000
2 lots 20,000 HK$ 8,000
3 lots 30,000 HK$ 12,000
4 lots 40,000 HK$ 16,000
5 lots 50,000 HK$ 20,000
6 lots 60,000 HK$ 24,000
7 lots 70,000 HK$ 28,000
8 lots 80,000 HK$ 32,000
9 lots 90,000 HK$ 36,000
10 lots 100,000 HK$ 40,000
20 lots 200,000 HK$ 80,000
30 lots 300,000 HK$ 120,000
40 lots 400,000 HK$ 160,000
50 lots 500,000 HK$ 200,000
60 lots 600,000 HK$ 240,000
70 lots 700,000 HK$ 280,000
80 lots 800,000 HK$ 320,000
90 lots 900,000 HK$ 360,000
100 lots 1,000,000 HK$ 400,000
200 lots 2,000,000 HK$ 800,000
300 lots 3,000,000 HK$ 1,200,000
400 lots 4,000,000 HK$ 1,600,000
500 lots 5,000,000 HK$ 2,000,000
600 lots 6,000,000 HK$ 2,400,000
700 lots 7,000,000 HK$ 2,800,000
800 lots 8,000,000 HK$ 3,200,000
900 lots 9,000,000 HK$ 3,600,000
1,000 lots 10,000,000 HK$ 4,000,000
1,200 lots 12,000,000 HK$ 4,800,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,400 lots 14,000,000 HK$ 5,600,000
1,600 lots 16,000,000 HK$ 6,400,000
1,712 lots 17,120,000 HK$ 6,848,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 63.9M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +15105%

Valuation & Financials

Market Cap (at Offer Price)HK$ 822,000,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣10.3百萬元
Period-End Cash Balance人民幣49.4百萬元
Listing Expenses~HK$ 63,900,000
Listing Expenses / Funds Raised~46.64%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201720182019
Revenue 112,932158,935191,156
Cost of sales -38,390-66,442-90,118
Gross profit 74,54292,493101,038
Other income and gains, net 655921,626
Selling and distribution expenses -37,020-44,667-50,172
Administrative expenses -12,392-18,489-33,405
Operating profit 24,69329,67418,724
Net finance costs -1,361-3,291-2,336
Profit before tax 23,33226,38316,388
Income tax expense -5,927-7,965-6,111
Profit for the year 17,40518,41810,277
Profit attributable to owners 17,37917,8559,897
Balance Sheet
Item 2017201820192020-06
Cash and cash equivalents 9,41820,35549,410
Trade and bills receivables 4,3815,0978,321
Total current assets 32,38942,59993,307
Total current liabilities 54,85881,01070,068
Total equity 15,66714,99093,275
Equity attributable to owners 16,28115,04193,058
Interest-bearing borrowings 006,94815,005
Cash Flow Statement
Item 2017201820192020-06
Net cash from operating activities 34,54832,05716,981
Depreciation of PP&E 4,2954,9085,7843,640
Depreciation of right-of-use assets 3,1823,5855,9022,920
Amortisation of intangible assets 31556716
Purchase of PP&E -2,611-12,723-10,832-1,567
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 0.435
First Day OpenHK$ 0.475
First Day Change8.75%
First Day Volume819968000.0
First Day Turnover386834000.0
Use of Proceeds
1、約28.0%,或19.7百萬港元,將用作翻新所有現有醫療美容機構并擴張杭州瑞麗、瑞麗天鴿及蕪湖瑞麗,以提升能力、更新品牌形象及擴大市場份額; 2、約28.0%,或19.7百萬港元,將用作為上海市新建醫療美容機構的資本支出及初始營運成本提供資金; 3、約15.0%,或10.6百萬港元,將用作中國浙江省醫療美容機構的潛在戰略收購; 4、約11.0%,或7.8百萬港元,將用作購買醫療美容服務設備及醫療消耗品,以完善若干醫療美容診療,擴大醫療美容服務范圍; 5、約8.0%,或5.6百萬港元將用于積極推廣我們的品牌; 6、約10%,或7.0百萬港元,將用作一般營運資金及其他一般公司用途。

Underwriting Syndicate

Sole Sponsor (1)
INNOVAX CAPITAL LIMITED CE BDT371
Overall Coordinators (2)
AUSTRAX SECURITIES LIMITED CE BHV052 Apricot Capital (Hong Kong) Limited CE ACX624
Joint Bookrunners (5)
AUSTRAX SECURITIES LIMITED CE BHV052 Apricot Capital (Hong Kong) Limited CE ACX624 交银国际证券有限公司 CE APJ121 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685 First Fidelity Capital (International) Limited CE AMS441
Joint Lead Managers (9)
AUSTRAX SECURITIES LIMITED CE BHV052 Apricot Capital (Hong Kong) Limited CE ACX624 交银国际证券有限公司 CE APJ121 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685 First Fidelity Capital (International) Limited CE AMS441 Kirin Securities Limited CE BJB225 KINGKEY SECURITIES GROUP LIMITED CE AXG710 Realord Asia Pacific Securities Limited CE AVJ441 IMPERIUM INTERNATIONAL SECURITIES LIMITED CE AVI905

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 昊海生物科技控股有限公司 20,000,000 HKD — 14.60% — 6 months 2021-06-28
2 途益香港有限公司 10,000,000 HKD — 7.30% — 6 months 2021-06-28

Directors & Management

PositionChinese nameEnglish Name
Chairman傅海曙—
Company Secretary陳愛發—
No director data available.

Major Shareholders

Major Shareholders & Holdings傅海曙先生透過Ruide BVI間接持有本公司約53.98%股份;Ruide BVI為其全資投資控股公司,傅先生配偶金春苗女士被視為持有相同權益。其他主要股東包括美天下(6.28%)、上海東嫿(5.46%)及Huamei Medical(5.46%)等。
About this page

This page shows Raily Aesmed (02135) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect